Key result
Pretreatment with UP269-6 over 7 days produced more effective pharmacological AT1R blockade and cardioprotection after acute ischemia-reperfusion than losartan in dogs.
Why the study?
Does UP269-6 provide more effective AT1R blockade and cardioprotection during ischemia-reperfusion than losartan in dogs?
Does UP269-6 provide more effective AT1R blockade and cardioprotection during ischemia-reperfusion than losartan in dogs?
In a dog model, the novel AT1R antagonist UP269-6 provided superior cardioprotection and hemodynamic benefits during ischemia-reperfusion compared to losartan.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in a canine model; leaves open translation to human ischemia-reperfusion injury.
BACKGROUND: Whether pretreatment with the novel oral angiotensin II (AngII) type 1 receptor (AT(1)R) antagonist UP269-6 (UP) can produce more effective AT(1)R blockade than losartan (LN) for cardioprotection during ischemia-reperfusion (IR) in the dog has not been determined. METHODS AND MATERIALS: We compared the effect of UP (n = 5) and LN (n = 5) on serial in vivo hemodynamics, AngII pressor responses, and left ventricular (LV) volumes and function (echocardiograms) during escalation to optimal oral dosage over 7 days (day 0 to day 6), and acute IR (15 minutes ischemia, 30 minutes reperfusion) and ex vivo AT(1)R protein (Western immunoblots) with additional sham (n = 5) and IR (n = 5) controls on day 6. Compared with LN, UP produced greater vasodepression and decrease in diastolic volume during dose escalation and greater inhibition of the AngII pressor response over the range of escalating concentrations (0.05, 0.10, 0.25, and 0.50 microg/kg) on day 6. Acute IR after UP pretreatment resulted in less increase in LV filling pressure and LV diastolic and systolic volumes and greater ejection fraction, although UP and LN had similar effects on AT(1)R protein. CONCLUSION: Pretreatment with UP269-6 over 7 days produces more effective pharmacological AT(1)R blockade and cardioprotection after acute IR than LN in the dog.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2000) studied Ischemia-reperfusion (n=20). UP269-6 vs. Losartan was evaluated on Hemodynamics, AngII pressor responses, and left ventricular volumes and function. Pretreatment with UP269-6 over 7 days produced more effective pharmacological AT1R blockade and cardioprotection after acute ischemia-reperfusion than losartan in dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: